jCyte, Inc   Report issue

For profit Phase 2
Founded: Newport Beach CA United States (2012)

Organization Overview

First Clinical Trial
2015
NCT02320812
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

jCyte, Inc

Active Ingredients

Drugs in Phase 2 Trials (1)

human retinal progenitor cells (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1